<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is the precursor lesion of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, whose progression follows sequential stages </plain></SENT>
<SENT sid="1" pm="."><plain>However, the low progression rate and the inadequacy and subjective interpretation of histologic grading in predicting <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> progression call for more objective biomarkers that can improve risk prediction </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a genome-wide profiling of 754 human microRNAs (miRNA) in 35 <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium, 34 <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and 36 esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues using TaqMan real-time PCR-based profiling </plain></SENT>
<SENT sid="3" pm="."><plain>Unsupervised hierarchical clustering using 294 modestly to highly expressed miRNAs showed clear clustering of two groups: <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium versus <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>/esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, there was an excellent clustering of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> (without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) tissues from <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium tissues </plain></SENT>
<SENT sid="5" pm="."><plain>However, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> tissues of different stages and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues were interspersed </plain></SENT>
<SENT sid="6" pm="."><plain>There were differentially expressed miRNAs at different stages </plain></SENT>
<SENT sid="7" pm="."><plain>The majority of miRNA aberrations involved upregulation of expression in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues, with the most dramatic alterations occurring at the Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> stage </plain></SENT>
<SENT sid="8" pm="."><plain>Known oncomiRs, such as miR-21, miR-25, and miR-223, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor miRNAs, including miR-205, miR-203, let-7c, and miR-133a, showed progressively altered expression from <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>We also identified a number of novel miRNAs that showed progressively altered expression, including miR-301b, miR-618, and miR-23b </plain></SENT>
<SENT sid="10" pm="."><plain>The significant miRNA alterations that were exclusive to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> but not <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> included miR-375 downregulation and upregulation of five members of the miR-17-92 and its homologue clusters, which may become promising biomarkers for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> development </plain></SENT>
</text></document>